● BIOLOGY IS CODE — THE BIOLOGICAL OPERATING SYSTEM
We are moving from reactive chemistry to a predictive Biological OS
Companies bridging the gap between molecular reality and AI computation are generating the largest asymmetric wealth-creation event of the decade. The thesis reduces to three verbs: Read the code, orchestrate the data, write the biology.
Read the CodeOrchestrate the DataWrite the Biology
Snapshot · Jun 25, 2026 · 9 tickers
The new scaling law is Healthspan per Token
Old scaling laws governed software: more parameters → more intelligence. The next massive consumer reallocation of capital is biological. Consumers exhibit near-full price elasticity for platforms that demonstrably add years of healthy life — bending the curve from traditional aging (1 year lived = 1 year lost) toward longevity escape velocity, where predictive ontologies return more than a year of healthspan per year lived.
"SICKNESS IS SIMPLY A BUG IN THE PROTEOMIC NETWORK"
Level 5Clinical outcomes
Human health, lifespan, systemic performance.
Level 4Proteins & proteoforms
3D Lego-like structures that execute function. Disfunction here is the root of all disease.
Level 3Peptides
Short chains — the body’s biological instruction set.
Level 2Amino acids & chemistry
Raw dietary inputs and chemical compilers.
Level 1Atoms
The lowest level of abstraction — the physical hardware.
To fix a bug at Level 5, AI must compute the physics of Level 1 and write code via Level 3. Read the proteome, then write back with precision.
MAPPING THE BIO-OS VALUE CHAIN
READ
Data extraction
Nautilus ($NAUT)
10B-protein mapping; Tau proteoforms / neuro.
Tempus & Caris ($TEM / $CAI)
Deep oncology data integrated with hospitals.
Recursion ($RXRX)
Wetlab simulation lowering chemical toxicity.
ORCHESTRATE
Distribution & inference
Hims ($HIMS)
D2C infrastructure, longitudinal biomarker aggregation — the incentive provider that owns the consumer.
WRITE
Biological intervention
ImmunityBio ($IBRX)
Immune-system reboot (IL-15 superagonist).
MiNK ($INKT)
Immune bypass — iNKT cells / stable lipids.
NervGen ($NGEN)
Nervous-system regeneration (NVG-291).
Parabilis ($PBLS)
Solving flat-protein errors (Helicon peptides).
Read and Write are brilliant tools, but they lack the end-consumer relationship. The platform that owns distribution and provides incentives (the D2C ontological flywheel) captures the majority of the economic value — an insurmountable "singularity scaler."
MARKET CAP · Jun 25, 2026
TEM
$52
READ
Tempus AI
Deep oncology data, integrated with hospitals.
$9.3B
HIMS
$33
ORCHESTRATE
Hims & Hers Health
D2C rails, longitudinal biomarkers, the incentive provider.
$7.8B
IBRX
$7.10
WRITE
ImmunityBio
Immune system reboot (IL-15 superagonist).
$7.4B
CAI
$17
READ
Caris Life Sciences
Molecular profiling, blood + tissue. IPO Jun 2025.
$4.9B
PBLS
$27
WRITE
Parabilis Medicines
Helicon peptides for flat / undruggable proteins. IPO Jun 2026.
10B-protein mapping. Focus: Tau proteoforms / neuro.
$286M
NGEN
$2.10
WRITE
NervGen Pharma
Nervous-system regeneration (NVG-291). Nasdaq Jan 2026.
$210M
INKT
$11.87
WRITE
MiNK Therapeutics
Immune bypass — iNKT cells target stable lipids, not peptides.
$60M
INCOME STATEMENTS · annual · USD millions
Hims & Hers Health
HIMS · ≈ $33/sh · ORCHESTRATE
Market cap
$7.8B
Revenue
CAGR +65% · Total +346%
Gross profit
CAGR +62% · Total +324%
Operating income
CAGR -15% · Total +254%
FY2022–FY2025. The orchestrator: revenue compounded to $2.35B (+59% in 2025) and operating income turned positive in 2024–2025. Real gross margins (~74%) fund the D2C flywheel.
The compute required for biology dwarfs today\u2019s AI infrastructure
Every H100 GPU installed on Earth would provide only ~0.02% of the compute needed to build an exhaustive proteomic map of a single human for a single year. We are at the absolute infancy of biological computation — the singularity scalers that solve this bottleneck can eclipse the scale of today\u2019s tech giants.
METODOLOGÍA & NOTAS
Market caps and prices are a point-in-time snapshot (Jun 25, 2026) and move daily.
Income-statement figures are annual GAAP from company filings and Yahoo Finance. NAUT and INKT are pre-revenue, so only operating income is plotted.
CAI (IPO Jun 2025) shows only FY2024–FY2025; its gross profit is estimated from margin and its operating income is approximate (2025 distorted by IPO stock comp).
IBRX operating income for 2022 and 2025 is approximate (derived from R&D + SG&A).
PBLS (IPO Jun 2026) and NGEN (Nasdaq Jan 2026) are pre-revenue with limited public history — shown as info cards, not charts.
This is data and research context, not investment advice.
← 10am.pro